7:01AM Compugen discloses discovery of five potential cancer targets for antibody drug conjugate therapy (CGEN) 9.18 : Co announces the predictive discovery and selection of five candidate targets for antibody-drug conjugate cancer therapy. These five potential ADC targets, representing the initial results from the Company's second focused in silico discovery program, are now entering initial experimental validation to be followed by antibody discovery and development activities. Initial results are expected during the second half of 2014.
ADC target discovery is Compugen's second focused in silico discovery program, following the success of its first focused discovery program for the discovery of immune checkpoint targets for treatment of cancer and immune diseases.
News 
Market Data 
Discover 
